The doc points to legitimate concerns about
overseas generic drugs, but those may not apply to Mezavant, which is overseas name brand.
https://www.eurekalert.org/pub_releases/2008-10/sp-sar100308.php said...
Shire has licensed from Giuliani SpA the exclusive rights to develop and commercialize LIALDA in the US, Canada, Pacific Rim, and Europe (excluding Italy). LIALDA is known as MEZAVANT XL™ in the UK and Ireland, and MEZAVANT® elsewhere outside of the US. Giuliani SpA retains the development and commercialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the MMX technology.
It is possible the pharmacy would fill a Lialda prescript
ion with Mezavant since they are exchangable names internationally.
A prescript
ion for Mesavant would make things easier. But the prescript
ion must not be marked to allow generic substitution, or the pharmacy might replace with a generic mesalamine that had uncertain manufacture, and might not even be the once a day MMX technology in Lialda.
good luck